J&J to pay $117M to settle pelvic mesh suits

Johnson & Johnson and its subsidiary Ethicon will pay nearly $117 million to settle claims that they misrepresented the risks of transvaginal surgical mesh devices, according to The Wall Street Journal.

Attorneys general in 41 states and Washington, D.C., claim J&J and Ethicon knew medical complications could arise from using the device but didn't adequately warn consumers or surgeons.

Transvaginal surgical mesh devices are used to treat pelvic organ prolapse, a condition that causes the bladder, bowel or uterus to shift, often after a hysterectomy, childbirth or menopause. Health complications linked to the devices include urinary dysfunction, loss of sexual function, constipation, pelvic pain and infection.

The settlement involves no admission of liability or misconduct from Ethicon.

Read the full article here.

More articles on pharmacy:
Novant Health to open health clinics inside Walgreens
GlaxoSmithKline recalls prescription heartburn drug globally
BIO CEO to step down at the end of 2020

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers